{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
fedratinib
to a specific field?
There is one exact (name or code) match for fedratinib
Status:
US Approved Rx
(2019)
Source:
NDA212327
(2019)
Source URL:
First approved in 2019
Source:
NDA212327
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Fedratinib (SAR-302503, TG-101348) is a selective small-molecule inhibitor of Janus kinase-2. Fedratinib demonstrated therapeutic efficacy in a murine model of myeloproliferative disease. Sanofi was developing Fedratinib for the treatment of myeloproliferative diseases and solid tumors.
The clinical development of fedratinib was terminated after reports of Wernicke's encephalopathy in myelofibrosis patients.
Status:
US Approved Rx
(2019)
Source:
NDA212327
(2019)
Source URL:
First approved in 2019
Source:
NDA212327
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Fedratinib (SAR-302503, TG-101348) is a selective small-molecule inhibitor of Janus kinase-2. Fedratinib demonstrated therapeutic efficacy in a murine model of myeloproliferative disease. Sanofi was developing Fedratinib for the treatment of myeloproliferative diseases and solid tumors.
The clinical development of fedratinib was terminated after reports of Wernicke's encephalopathy in myelofibrosis patients.
Status:
Possibly Marketed Outside US
Source:
Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125416
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT01996267: Phase 3 Interventional Active, not recruiting Breast Cancer
(2013)
Source URL:
Class:
PROTEIN
